Revolution Medicines Announces FDA Approval for RASONQUE™ in Pancreatic Cancer

On August 26, 2026, Revolution Medicines, Inc. announced a significant regulatory milestone: the U.S. Food and Drug Administration (FDA) has approved RASONQUE™ (daraxonrasib). The approval is for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have previously undergone systemic therapy or are not candidates for multiagent therapy.

This approval was based on positive data from the global, randomized Phase 3 clinical trial, RASolute 302. The company has confirmed that the once-daily oral tablets are now available for prescription in the United States. The wholesale acquisition cost has been set at $39,800 for a 30-day supply. This event marks a pivotal moment for Revolution Medicines, transitioning it to a commercial-stage company and providing a new therapeutic option for a patient population with high unmet medical need.